AETNA BETTER HEALTH® Coverage Policy/Guideline					
Name:	Synarel			Page:	1 of 5
Effective Date:	10/25/2023			Last Review Date:	10/2023
Applies to:	☐Illinois ☒New Jersey ☒Pennsylvania Kids	☐Florida ☒Maryland ☒Virginia		☒Florida Kids ☐Michigan ☐Kentucky PRMD	

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Synarel under the patient's prescription drug benefit.

Description:

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications
   1. Central precocious puberty
      Synarel is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes.
   2. Endometriosis
      Synarel is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. Experience with Synarel for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.

B. Compendial Uses
   1. Uterine leiomyomata (fibroids)
   2. Hirsutism
   3. Preservation of ovarian function in patients with cancer
   4. Prevention of recurrent menstrual related attacks in acute porphyria

All other indications are considered experimental/investigational and are not medically necessary.

Applicable Drug List:

Synarel

Policy/Guideline:

Documentation:
Submission of the following information is necessary to initiate the prior authorization review: For central precocious puberty, laboratory report or medical record of a pubertal

response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third-generation luteinizing hormone (LH) assay.

Criteria for Initial Approval:

A. Central precocious puberty (CPP)

Note: Requests for Synarel require that the patient is unable to take leuprolide acetate injection kit 1mg/0.2mL for the given diagnosis due to a trial and inadequate treatment response or intolerance, or a contraindication.

1. Authorization of 12 months may be granted for treatment of CPP in a female member when all of the following criteria are met:
   i. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging (e.g., computed tomography [CT] scan, magnetic resonance imaging [MRI]).
   ii. The diagnosis of CPP has been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third-generation luteinizing hormone (LH) assay.
   iii. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   iv. The member was less than 8 years of age at the onset of secondary sexual characteristics.
2. Authorization of 12 months may be granted for treatment of CPP in a male member when all of the following criteria are met:
   i. Intracranial tumor has been evaluated by appropriate lab tests and diagnostic imaging (e.g., CT scan, MRI).
   ii. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third-generation LH assay.
   iii. The assessment of bone age versus chronological age supports the diagnosis of CPP.
   iv. The member was less than 9 years of age at the onset of secondary sexual characteristics.

B. Endometriosis

Authorization of a total of 6 months may be granted to members for treatment of endometriosis.

C. Uterine leiomyomata (fibroids)

Authorization of up to 3 months may be granted for initial treatment of uterine leiomyomata (fibroids) when either of the following criteria is met:

1. Member has anemia due to uterine leiomyomata, or
2. The requested medication will be used prior to surgery for uterine leiomyomata.

D. Hirsutism

Authorization of a total of 6 months may be granted to members for the treatment of hirsutism.

E. Preservation of ovarian function in patients with cancer

Authorization of 3 months may be granted for preservation of ovarian function when the member is premenopausal and undergoing chemotherapy.

F. Prevention of recurrent menstrual related attacks in acute porphyria

Authorization of 12 months may be granted for prevention of recurrent menstrual related attacks in members with acute porphyria when the requested medication is prescribed by or in consultation with a physician experienced in the management of porphyrias.

Continuation of Therapy:

A. Central precocious puberty (CPP)

1. Authorization of up to 12 months may be granted for continuation of therapy for CPP in a female member if the member is currently less than 12 years of age and the member meets both of the following:
   i. The member is currently receiving the requested medication through a paid pharmacy or medical benefit.
   ii. The member is not experiencing treatment failure (e.g., clinical pubertal progression, lack of growth deceleration, continued excessive bone age advancement).
2. Authorization of up to 12 months may be granted for continuation of therapy for CPP in a male member if the member is currently less than 13 years of age and the member meets both of the following:
   i. The member is currently receiving the requested medication through a paid pharmacy or medical benefit.
   ii. The member is not experiencing treatment failure (e.g., clinical pubertal progression, lack of growth deceleration, continued excessive bone age advancement).

B. Uterine leiomyomata (fibroids)

Authorization of up to 3 months (for a lifetime maximum of 6 months total) may be granted for retreatment of uterine leiomyomata (fibroids) when either of the following criteria is met:

1. Member has anemia due to uterine leiomyomata, or
2. The requested medication will be used prior to surgery for uterine leiomyomata.

C. All other indications

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

Approval Duration and Quantity Restrictions:

Approval:

- CPP: 12 months
- Endometriosis, hirsutism: up to 6 months
- Preservation of ovarian function: 3 months
- All others: 12 months

References:

1. Synarel [package insert]. New York, NY: Pfizer Inc.; January 2023.
2. Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. *Clin Pediatr*. 2015;54:414-424.
3. Carel J, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752-e762.
4. Bangalore Krishna K, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: Update by an international consortium. *Horm Res Paediatr*. 2019;91(6):357-372.
5. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. *Pediatrics*. 2009;123:e1059-e1063.
6. Kaplowitz P, Bloch C, the Section on Endocrinology. Evaluation and referral of children with signs of early puberty. *Pediatrics*. 2016;137:e20153732.
7. Moore HCF, Unger JM, Phillips K-A, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015;372:923-32. doi:10.1056/NEJMoa1413204.
8. Clowse MEB, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. *J Womens Health (Larchmt)*. 2009 Mar;18(3):311–319. doi:10.1089/jwh.2008.0857
9. Stein P, Badminton M, Barth J, et al; British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Ann Clin Biochem*. 2013 May;50(Pt 3):217-23.
10. Innala, E, Bäckström, T, Bixo, M, Andersson, C. Evaluation of gonadotrophin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. *Acta Obstet Gynecol Scand*. 2010;89(1):95–100.
11. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2022. URL: http://www.clinicalpharmacology.com. Accessed May 2, 2023.

12. Minaguchi H, Wong JM, Snabes MC. Clinical use of nafarelin in the treatment of leiomyomas: a review of the literature. *J Reprod Med*. 2000;45:481-9.
13. Chrisp P, Goa KL. Nafarelin: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in sex hormone-related conditions. *Drugs*. 1990;39:523-51.
14. Heiner JS, Greendale GA, Kawakami AK, et al. Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism. *J Clin Endocrinol Metab*. 1995;80:3412-8.
15. Urman B, Yakin K. Ovulatory disorders and infertility. *J Reprod Med*. 2006;51(4):267-282.
16. National Institute for Health and Clinical Excellence (NICE). Guideline on assessment and treatment for people with fertility problems. NICE 2013 Feb 20:CG156.
17. Wong JM, Forrest KA, Snabes MC, et al. Efficacy of nafarelin in assisted reproduction technology: a meta-analysis. *Hum Reprod Update*. 2001;7:92-101.
18. Elgendy M, Afnan M, Holder R, et al. Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: effect on ovarian response and in-vitro fertilization outcome. *Hum Reprod*. 1998;13:2382-5.
19. Casper RF. Reducing the Risk of OHSS by GnRH Agonist Triggering. *J Clin Endocrinol Metab.* 2015;100(12):4396-8.
20. Cheuiche AV, da Silveira LG, de Paula LCP, et al. Diagnosis and management of precocious sexual maturation: an updated review. *Eur J Pediatr*. 2021;180(10):3073-3087.